Hunan Hansen Pharmaceutical002412.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Hunan Hansen Pharmaceutical (002412.SZ) trades at a P/E of 17.60x, P/B of 1.78x, P/S of 4.36x, and a dividend yield of 3.64%.
Longitudinal percentile comparison: P/E sits at the 20th percentile over the trailing 10Y window (vs. 65th percentile over 3Y); P/B sits at the 40th percentile over the trailing 10Y window (vs. 83rd percentile over 3Y); P/S sits at the 58th percentile over the trailing 10Y window (vs. 90th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 16th percentile within its industry and the 20th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.64%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 19.3 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Hunan Hansen Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002412 · SZSE: 002412 · 002412
Want the full picture on whether Hunan Hansen Pharmaceutical (002412.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 17.60 | ||||||
| P/B (MRQ) | 1.78 | ||||||
| P/S (TTM) | 4.36 | ||||||
| Dividend Yield | 3.64% | ||||||
| Buyback + Div Yield | 3.64% |